publicity photo in suit
Jay Short

Jay M. Short is founder and CEO of the antibody drug company BioAtla, LLC.[1] He was vice president of research and operations at Stratagene (now Agilent Technologies), president of the Stratagene antibody subsidiary Stratacyte, then founder and CEO of Diversa until 2005.[2] While at Diversa, Short invented methods of protein and pathway discovery via metagenomics, in addition to evolution technologies gene site saturation mutagenesis (GSSM) and GeneReassembly,[3] and was the first to combine these discovery and evolution technologies.

On December 7, 2015, San Diego-based BioAtla signed a license and option deal with Pfizer, involving BioAtla's conditionally-active biologics (CAB) antibody platform and Pfizer's antibody-drug conjugate (ADC) payloads.[4] BioAtla is eligible to receive more than $1.0 billion in up-front, regulatory and sales milestone commitments as well as tiered marginal royalties reaching double digits on potential future product sales.[5]

Short is also founder of the E. O. Wilson Biodiversity Foundation,[6] chairman of the board of Ciris Energy,[7] and member of the board of directors of Senomyx.[8] Short received his Ph.D. in biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in chemistry from Taylor University in Upland, Indiana.

References

  1. ↑ "PROFILE: Diversity in vision and expertise: Jay Short promotes sustainable bioscience". Industrial Biotechnology. 3 (1): 13–18. 1 March 2007. doi:10.1089/ind.2007.3.013.
  2. ↑ Somers, Terri (October 7, 2005). "Diversa CEO resigns from biotech". The San Diego Union-Tribune. Retrieved 12 August 2011.
  3. ↑ "Archived copy" (PDF). Archived from the original (PDF) on 2016-03-04. Retrieved 2015-12-15.{{cite web}}: CS1 maint: archived copy as title (link)
  4. ↑ "BioAtla Enters Into Strategic License And Option Agreement With Pfizer For A New Class Of Antibody Therapeutics". PR Newswire. 7 December 2015. Retrieved 9 December 2015.
  5. ↑ "ADCs take CAB ride to tumor-town: $1B deal with Pfizer sets Bioatla on development road". BioWorld. 8 December 2015. Retrieved 9 December 2015.
  6. ↑ "Foundation History". Web site.
  7. ↑ "An alternative to fracking?". San Diego Union-Tribune. 24 February 2013.
  8. ↑ "Jay M. Short, Ph.D. Joins the Board of Directors of Senomyx, Inc". PR Newswire. 13 April 2004. Retrieved 11 May 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.